HC Wainwright Estimates Kairos Pharma Q1 Earnings

Analysts project losses as biotech firm focuses on rare disease treatments

Apr. 3, 2026 at 11:08am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, metallic pharmaceutical manufacturing equipment, conveying a sense of industrial power and scientific precision through its heavy, imposing design.Kairos Pharma's specialized equipment and manufacturing processes are crucial to developing its pipeline of rare disease treatments.Cambridge Today

Kairos Pharma, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, has received Q1 2026 earnings estimates from HC Wainwright analysts. The analysts project Kairos will report a loss of $0.07 per share for the quarter as the company continues to develop small-molecule therapies to treat genetic diseases caused by nonsense mutations.

Why it matters

Kairos Pharma's proprietary platform aims to promote the readthrough of premature stop codons, with the goal of restoring production of full-length functional proteins for rare pediatric and orphan indications. As a clinical-stage biotech firm, Kairos' financial performance and pipeline progress are closely watched by investors and the broader pharmaceutical industry.

The details

In their research report, HC Wainwright analysts also provided estimates for Kairos Pharma's future quarterly earnings, projecting losses of $0.08 per share in Q2 2026, $0.09 per share in Q3 2026, and $0.12 per share in Q4 2026. Kairos Pharma's stock opened at $0.58 per share on Friday, April 3rd, 2026, with a market capitalization of $12.44 million. The company's shares have traded between $0.40 and $2.11 over the past 52 weeks, with a current 52-week moving average of $0.62.

  • Kairos Pharma's Q1 2026 earnings report is expected on Thursday, April 2nd, 2026.
  • The company's stock opened at $0.58 per share on Friday, April 3rd, 2026.

The players

Kairos Pharma, Ltd.

A clinical-stage biopharmaceutical company focused on developing small-molecule therapies to treat genetic diseases caused by nonsense mutations. The company's proprietary platform aims to promote readthrough of premature stop codons to restore production of full-length functional proteins.

HC Wainwright

A stock research and investment banking firm that issued Q1 2026 earnings estimates for Kairos Pharma.

J. Pantginis

An analyst at HC Wainwright who provided the Q1 2026 earnings estimates for Kairos Pharma.

Got photos? Submit your photos here. ›

What they’re saying

“HC Wainwright analyst J. Pantginis expects that the company will earn ($0.07) per share for the quarter.”

— J. Pantginis, Analyst

What’s next

Kairos Pharma is expected to report its full Q1 2026 financial results on Thursday, April 2nd, 2026.

The takeaway

As a clinical-stage biotech firm focused on rare genetic diseases, Kairos Pharma's financial performance and pipeline progress are closely watched by investors and the broader pharmaceutical industry. The projected Q1 2026 loss highlights the company's continued investment in its proprietary platform and drug development efforts.